EValuating trEatment RESponses of Dupilumab Versus Omalizumab in Type 2 Patients

NCT04998604 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

360

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Rhinosinusitis With Nasal Polyps
Asthma

Interventions

DRUG: Dupilumab
DRUG: Omalizumab
DRUG: Placebo

Sponsor

Sanofi

Collaborators

[object Object]